[Failure of elliptinium acetate in the treatment of unresectable hepatocarcinoma (phase II trial)].

Abstract

Fifteen patients with hepatocellular carcinoma were administered elliptinium acetate in a phase II trial. A dose of 80 mg/m2/day was administered during 3 consecutive days, every 3 weeks. According to WHO criteria regarding response, no objective responses were observed. The major toxicity was dryness of the mouth which occurred in 73% of patients, on addition, one case of hemolysis was documented in spite of a systematic search for anti-elliptinium antibodies prior to each injection. In conclusion, elliptinium acetate has no valuable therapeutic impact on the treatment of hepatocellular carcinoma.

• Authors: P Rougier, M Ychou, J P Droz
• Journal: Bulletin du cancer (Bull Cancer) Vol. 75 Issue 10 Pg. 979-81 ( 1988) ISSN: 0007-4551 [Print] France
• Vernacular Title: Echic de l'acetate d'elliptinium dans le traitement de l'hepatocarcinome inopérable (essai phase II).
• PMID: 2851337 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Alkaloids
• Antineoplastic Agents
• Ellipticines
• elliptinium

Topics

• Aged
• Alkaloids (therapeutic use)
• Antineoplastic Agents (adverse effects, therapeutic use)
• Carcinoma, Hepatocellular (drug therapy)
• Clinical Trials as Topic
• Ellipticines (adverse effects, therapeutic use)
• Female
• Humans
• Liver Neoplasms (drug therapy)
• Male
• Middle Aged